Tracer announces partnership with AstraZeneca and Series A financing

AstraZeneca Partnership

‍

Today we’re excited to announce Tracer’s new partnership with AstraZeneca to bring ctDNA monitoring into clinical trials.

Tracer has been working for several years on developing better and better ways to quantify cancer in patients. Doing so has obvious benefits: evaluate whether a treatment works , determine when a patient is cancer-free, and monitor for recurrence.

We’re lucky to be living in a time when new technologies are being developed to attack this problem. At Tracer, we’ve been able to leverage advances in NGS, dPCR, computation, and robotics to develop cost-effective, sensitive, scalable solutions for measuring ctDNA-levels in the blood. Recently, we launched our tumor-informed dPCR test. Researchers running oncology clinical trials are using it to better understand disease.

‍

Financing

In parallel, we’re announcing our Series A financing.

Tracer has raised capital from several incredible investors who are helping position the company to bring cancer detection technology to the clinic and biopharma. The round was led by GKCC, with participation from Great Oaks, Exor, Quiet, Pareto, Caffeinated, and others. With this capital, Tracer will continue to innovate to create and distribute scalable and accessible technologies for ctDNA detection

‍

‍

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

NEW YORK, New York, December12, 2024 — Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN).  

The agreement will enable AstraZeneca to use Tracer’s circulating tumor DNA (ctDNA) monitoring technology for clinical trials.  Tracer has developed a proprietary platform for tumor-informed ctDNA detection based on digital polymerase chain reaction (PCR). Tracer’s platform optimizes ctDNA detection, enabling cost-effective, precise, and scalable testing for patients as an alternative to radiographic imaging.

“We are entering a new era of oncology where patients will no longer have to wait for costly and imprecise radiographic scans to assess treatment and disease progression,” said Mark Kaganovich, CEO of Tracer Biotechnologies. “We are proud to work with AstraZeneca to leverage frequent, precise ,and cost-effective ctDNA measurement for minimal residual disease detection and treatment response monitoring.”

About Tracer Biotechnologies

Tracer Biotechnologies is a next-generation diagnostics company.  Tracer is the only ultrasensitive ctDNA assay for Molecular Response surveillance. Combining tumor-informed personalization with dPCR allows Tracer to offer cost-effective assays for an unlimited number of timepoints on a study. The Tracer assay is available for blood and urine.

‍

‍

‍